Crestline Management LP Reduces Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

Crestline Management LP reduced its stake in Sana Biotechnology, Inc. (NASDAQ:SANA) by 7.3% during the 4th quarter, Holdings Channel reports. The fund owned 2,860,937 shares of the company’s stock after selling 224,687 shares during the period. Crestline Management LP’s holdings in Sana Biotechnology were worth $4,663,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in SANA. Boxer Capital Management LLC acquired a new position in Sana Biotechnology in the 4th quarter valued at about $2,518,000. Corient Private Wealth LLC lifted its stake in shares of Sana Biotechnology by 161.7% during the fourth quarter. Corient Private Wealth LLC now owns 1,182,699 shares of the company’s stock valued at $1,928,000 after buying an additional 730,699 shares during the period. Dimensional Fund Advisors LP boosted its position in Sana Biotechnology by 44.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,557,496 shares of the company’s stock worth $2,538,000 after acquiring an additional 478,596 shares during the last quarter. Renaissance Technologies LLC grew its stake in Sana Biotechnology by 1,838.3% in the 4th quarter. Renaissance Technologies LLC now owns 319,818 shares of the company’s stock worth $521,000 after acquiring an additional 303,318 shares during the period. Finally, Jane Street Group LLC grew its stake in Sana Biotechnology by 287.2% in the 4th quarter. Jane Street Group LLC now owns 367,855 shares of the company’s stock worth $600,000 after acquiring an additional 272,862 shares during the period. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Price Performance

Shares of NASDAQ:SANA opened at $1.71 on Wednesday. The business has a 50-day moving average of $1.98 and a two-hundred day moving average of $2.52. The firm has a market capitalization of $385.57 million, a PE ratio of -1.22 and a beta of 1.75. Sana Biotechnology, Inc. has a 12 month low of $1.26 and a 12 month high of $10.23.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. As a group, research analysts anticipate that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Analysts Set New Price Targets

SANA has been the topic of a number of recent analyst reports. Citizens Jmp raised Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research note on Tuesday, March 18th. Jefferies Financial Group assumed coverage on Sana Biotechnology in a research note on Friday, March 14th. They issued a “buy” rating and a $7.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Sana Biotechnology in a research note on Thursday, April 24th. Finally, TD Cowen raised shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday, January 8th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.80.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.